REG - FIL Limited Allergan PLC - Form 8.3 - Abbvie Inc

AbbvieAnnouncement

11/05/2020 15:20

RNS Number : 5286M
  
FIL Limited
  
11 May 2020
  
 

Ap19
 
 
FORM 8.3
 
IRISH TAKEOVER PANEL
 
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
 
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
 
1.       KEY INFORMATION
 




Name of person dealing (Note 1)


FMR LLC and/or one or more of its direct or indirect subsidiaries
And
FIL Limited and/or one or more of its direct and indirect subsidiaries




Company dealt in


ABBVIE INC




Class of relevant security to which the dealings being disclosed relate (Note 2)


ORDINARY SHARES




Date of dealing


08-May-2020




2.         INTERESTS AND SHORT POSITIONS
 
(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)




 


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


32,565,242                 2.20%


 




(2) Derivatives (other than options)


 


 




(3) Options and agreements to purchase/sell


 


 




Total


32,565,242                 2.20%


 



 
 
 
 
 
 
 



                                                                                      
THE ABOVE INCLUDES A TRANSFER OUT OF 6,215 ORDINARY SHARES
                                                                                  
 
(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)




Class of relevant security:


Long


Short




 


Number


 


(%)


Number


 


(%)




(1) Relevant securities


 


 




 
(2) Derivatives (other than options)


 


 




 
(3) Options and agreements to purchase/sell


 


 




Total


 


 



 
 
 
 
 
 
 




 

Ap20
 
 
1.       DEALINGS (Note 4)
 
(a)      Purchases and sales
 




Purchase/Sale


Number of relevant securities


Price per unit (Note 5)




Sale


3,650


82.89 USD/Share




Sale


3,488


83.02 USD/Share




Sale


15,908


83.10 USD/Share




Sale


10,500


83.12 USD/Share




Sale


4,715


83.14 USD/Share




Sale


1,275


83.18 USD/Share




Sale


5,364


83.22 USD/Share




Sale


5,100


83.23 USD/Share




Sale


1,100


83.26 USD/Share




Sale


3,538


83.27 USD/Share




Sale


1,899


83.29 USD/Share




Sale


2,263


83.31 USD/Share




Sale


1,000


83.56 USD/Share




Sale


11,800


83.58 USD/Share




Sale


8,744


83.60 USD/Share




Sale


7,400


83.61 USD/Share




Sale


1,153


83.64 USD/Share




Sale


4,403


83.67 USD/Share




Purchase


1,034


83.96 USD/Share




Sale


28


83.20 USD/Share




Purchase


2,097


83.36 USD/Share




Sale


11,681


83.43 USD/Share




Sale


1


83.37 USD/Share




Sale


1


83.44 USD/Share




Sale


1


83.49 USD/Share




Sale


1


83.50 USD/Share




Sale


1


83.52 USD/Share




Sale


1


83.54 USD/Share




Sale


1


83.56 USD/Share




Sale


2


83.57 USD/Share




Sale


1


83.58 USD/Share




Sale


1


83.61 USD/Share




Sale


1


83.70 USD/Share




Sale


1


83.75 USD/Share




Sale


1


83.77 USD/Share




Sale


1


83.85 USD/Share




Sale


1


83.89 USD/Share




Sale


1


84.00 USD/Share




Sale


1


84.01 USD/Share




Sale


2


84.02 USD/Share




Sale


1


84.04 USD/Share




Sale


1


84.06 USD/Share




Sale


1


84.10 USD/Share




Sale


1


84.14 USD/Share




 
 
 
(b)      Derivatives transactions (other than options transactions)
 




Product name,
e.g. CFD


Nature of transaction
(Note 6)


Number of relevant securities
(Note 7)


Price per unit
(Note 5)




 
(c)      Options transactions in respect of existing relevant securities
 
 
(i)       Writing, selling, purchasing or varying
 




Product name,
e.g. call option


Writing, selling, purchasing, varying etc.


Number of securities to which the option relates (Note 7)


Exercise price


Type, e.g. American, European etc.


Expiry date


Option money paid/received per unit (Note 5)




 


 


 


 


 


 


 




 
(ii)      Exercising
 




Product name,
e.g. call option


Number of securities


Exercise price per unit (Note 5)




 


 


 




 
(d)      Other dealings (including transactions in respect of new securities) (Note 4)
 




Nature of transaction
(Note 8)


Details


Price per unit
(if applicable) (Note 5)




 


 


 




Ap21
 
2.       OTHER INFORMATION
 
Agreements, arrangements or understandings relating to options or derivatives
 
 
 
 
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any 
relevant securities to which any derivative referred to on this form is referenced. 
If none, this should be stated.
 
 
 
 
 
 
 
 
 
Is a Supplemental Form 8 attached? (Note 9)                                            NO
 




Date of disclosure


11-May-2020




Contact name


Paul Clark




Telephone number


00353 1 223 1447




If a connected EFM, name of offeree/offeror with which connected


 




If a connected EFM, state nature of connection (Note 10)


 




 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
ISEKKDBDNBKDPPD